1.35
price down icon1.46%   -0.02
after-market Handel nachbörslich: 1.35
loading
Schlusskurs vom Vortag:
$1.37
Offen:
$1.35
24-Stunden-Volumen:
2.67M
Relative Volume:
1.62
Marktkapitalisierung:
$82.88M
Einnahmen:
$5.03M
Nettoeinkommen (Verlust:
$-185.41M
KGV:
-0.4369
EPS:
-3.09
Netto-Cashflow:
$-139.79M
1W Leistung:
+4.65%
1M Leistung:
-8.78%
6M Leistung:
-90.22%
1J Leistung:
-88.91%
1-Tages-Spanne:
Value
$1.31
$1.395
1-Wochen-Bereich:
Value
$1.22
$1.4093
52-Wochen-Spanne:
Value
$1.1001
$16.10

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name
Firmenname
Pliant Therapeutics Inc
Name
Telefon
650-481-6770
Name
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
171
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
PLRX's Discussions on Twitter

Vergleichen Sie PLRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PLRX
Pliant Therapeutics Inc
1.35 79.19M 5.03M -185.41M -139.79M -3.09
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-04 Fortgesetzt Cantor Fitzgerald Neutral
2025-03-04 Herabstufung Needham Buy → Hold
2025-03-03 Herabstufung Leerink Partners Outperform → Market Perform
2025-03-03 Herabstufung Stifel Buy → Hold
2025-02-10 Herabstufung Canaccord Genuity Buy → Hold
2025-02-10 Herabstufung Citigroup Buy → Neutral
2025-02-10 Herabstufung H.C. Wainwright Buy → Neutral
2025-02-10 Herabstufung JP Morgan Overweight → Neutral
2025-02-10 Herabstufung Oppenheimer Outperform → Perform
2025-02-10 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2025-02-10 Herabstufung Wells Fargo Overweight → Equal Weight
2024-09-09 Fortgesetzt Leerink Partners Outperform
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-05-18 Eingeleitet Canaccord Genuity Buy
2023-04-13 Eingeleitet Robert W. Baird Outperform
2022-12-14 Eingeleitet Stifel Buy
2022-12-07 Eingeleitet JP Morgan Overweight
2022-09-01 Eingeleitet Citigroup Buy
2022-07-20 Eingeleitet SVB Leerink Outperform
2022-05-25 Eingeleitet Cantor Fitzgerald Overweight
2021-12-10 Eingeleitet Oppenheimer Outperform
2021-11-24 Eingeleitet RBC Capital Mkts Outperform
2021-11-03 Eingeleitet H.C. Wainwright Buy
2021-04-20 Eingeleitet BTIG Research Buy
2021-04-05 Eingeleitet Citigroup Buy
2020-06-29 Eingeleitet Citigroup Buy
2020-06-29 Eingeleitet Cowen Outperform
2020-06-29 Eingeleitet Needham Buy
2020-06-29 Eingeleitet Piper Sandler Overweight
Alle ansehen

Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten

pulisher
May 21, 2025

Pliant Therapeutics presents new fibrosis treatment data By Investing.com - Investing.com Canada

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics Presents Clinical and Preclinical Data at th - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics presents new fibrosis treatment data - Investing.com

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference | PLRX Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society ... - Eagle-Tribune

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Breakthrough: Pliant's New Lung Disease Drug Outperforms Standard Treatment in Latest Clinical Data - Stock Titan

May 21, 2025
pulisher
May 14, 2025

How Are Things Looking For Pliant Therapeutics Inc (NASDAQ: PLRX) For The Short Term? - Stocksregister

May 14, 2025
pulisher
May 12, 2025

Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties - TipRanks

May 12, 2025
pulisher
May 09, 2025

Another Bay Area biotech company announces layoffs - MSN

May 09, 2025
pulisher
May 09, 2025

Pliant Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

Pliant (PLRX) Prepares to Release Topline Results from BEACON-IP - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Pliant (PLRX) Prepares to Release Topline Results from BEACON-IPF Trial | PLRX Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Pliant Therapeutics reports Q1 EPS (92c), consensus (62c) - TipRanks

May 08, 2025
pulisher
May 08, 2025

Pliant Therapeutics (PLRX) Advances in Clinical Trials and Oncology Research | PLRX Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 08, 2025
pulisher
May 07, 2025

Market Watch Highlights: Pliant Therapeutics Inc (PLRX) Ends on an Downturn Note at 1.43 - DWinneX

May 07, 2025
pulisher
May 05, 2025

Pliant Therapeutics Cuts Workforce by Nearly Half - Powder & Bulk Solids

May 05, 2025
pulisher
May 02, 2025

Bay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in value - MSN

May 02, 2025
pulisher
May 02, 2025

Pliant cuts workforce by 45% following lung trial termination - Clinical Trials Arena

May 02, 2025
pulisher
May 02, 2025

Pliant Therapeutics to cut 45% of workforce (PLRX:NASDAQ) - Seeking Alpha

May 02, 2025
pulisher
May 01, 2025

Pliant Therapeutics (PLRX) Restructures to Prolong Financial Res - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics Reduces Workforce as Part of Strategic Realignment - MarketWatch

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics (PLRX) Restructures to Prolong Financial Resources | PLRX Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics announces workforce reduction By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics announces workforce reduction - Investing.com

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics Announces Major Workforce Reduction - TipRanks

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical Trials - Nasdaq

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations - GlobeNewswire

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics Slashes Nearly Half its Workforce While Awaiting Crucial IPF Drug Results - Stock Titan

May 01, 2025
pulisher
May 01, 2025

You might want to take a look at Pliant Therapeutics Inc (PLRX) now - Sete News

May 01, 2025
pulisher
Apr 30, 2025

Pliant Therapeutics Inc [PLRX] stock was sold by Coulie Bernard at the price of US$0.59 million - knoxdaily.com

Apr 30, 2025
pulisher
Apr 30, 2025

Market Momentum: Pliant Therapeutics Inc (PLRX) Registers a 0.68 Increase, Closing at 1.48 - DWinneX

Apr 30, 2025
pulisher
Apr 30, 2025

Stock Performance Spotlight: Cg Oncology Inc (CGON) Ends the Day at 26.94, Down by -3.68 - DWinneX

Apr 30, 2025
pulisher
Apr 30, 2025

Pliant Therapeutics Inc (PLRX)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com

Apr 30, 2025
pulisher
Apr 29, 2025

Legal & General Group Plc Grows Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

Pliant Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - investchronicle.com

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 26, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - Louisiana First News

Apr 26, 2025
pulisher
Apr 25, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant ... - Bluefield Daily Telegraph

Apr 25, 2025
pulisher
Apr 25, 2025

Pliant Therapeutics discovers new integrin αvβ1, αvβ6 and/or αvβ8 antagonists - BioWorld MedTech

Apr 25, 2025
pulisher
Apr 25, 2025

Pliant Therapeutics Inc’s Market Journey: Closing Weak at 3.03, Down -1.62 - DWinneX

Apr 25, 2025
pulisher
Apr 24, 2025

PLRXPliant Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan

Apr 24, 2025
pulisher
Apr 24, 2025

Healthy Upside Potential: Pliant Therapeutics Inc (PLRX) - Sete News

Apr 24, 2025
pulisher
Apr 24, 2025

Market Recap Check: Pliant Therapeutics Inc (PLRX)’s Positive Finish at 1.54, Up/Down 2.67 - DWinneX

Apr 24, 2025
pulisher
Apr 23, 2025

Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Bought by JPMorgan Chase & Co. - Defense World

Apr 23, 2025

Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):